2. Disease Areas
  3. Blood or Cardio-cerebrovascular Disease
  4. Blood Disease
  5. Myelodysplastic Syndrome

Myelodysplastic Syndrome

Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, leading to peripheral cytopenias—particularly anemia, neutropenia, and thrombocytopenia—and a predisposition to progression into acute myeloid leukemia (AML), with approximately 10–20% of cases evolving to AML. The disease results from genetic and epigenetic abnormalities in bone marrow stem cells, causing dysplastic morphologic changes and impaired differentiation across myeloid lineages. MDS is defined pathologically by the presence of dysplasia in one or more blood cell lines, including ringed sideroblasts in certain subtypes, and is classified based on morphology, blast percentage, and cytogenetic features (e.g., refractory anemia, refractory anemia with excess blasts). It commonly affects older adults, with diagnosis typically occurring after age 60, and often remains under-recognized due to nonspecific symptoms such as fatigue, weakness, shortness of breath, infections, bruising, and bleeding. Risk factors include prior exposure to chemotherapy or radiation, and secondary MDS can arise following treatment for other cancers. Management strategies vary according to risk stratification and may include supportive care with transfusions, growth factors, hypomethylating agents, immunomodulatory drugs, chemotherapy, or allogeneic stem cell transplantation in eligible patients. MDS is considered a premalignant condition and requires careful monitoring due to its potential to transform into overt AML.

Myelodysplastic Syndrome (6):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-159520
    Ofirnoflastum 2731294-23-6 99.93%
    Ofirnoflastum (Ofirnoflast) is an orally active first-in-class allosteric NEK7 inhibitor with an IC50 of 46 nM. Ofirnoflastum binds an allosteric site adjacent to NEK7’s ATP-binding pocket, induces conformational shifts, disrupts NEK7-NLRP3 binding, blocks NLRP3 inflammasome assembly, spares NEK7’s physiological functions, and suppresses caspase-1, caspase-8, NF-κB, and TNF activity. Ofirnoflastum reduces pro-inflammatory cytokine production, suppresses ASC specks, IL-1β release, pyroptotic cell death, and leukemic burden, induces apoptosis and erythroid differentiation, restores hematopoiesis, and improves outcomes in colitis models. Ofirnoflastum can be used for the research of myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
    Ofirnoflastum
  • HY-19222
    CVS-1123 151275-19-3
    CVS-1123 is an orally active direct thrombin inhibitor. CVS-1123 inhibits in vitro platelet aggregation of γ-thrombin and prolongs activated partial thromboplastin time. CVS-1123 alters the thrombotic response to deep vessel wall damage in arterial and venous circulation. CVS-1123 can be used in antithrombotic studies
    CVS-1123
  • HY-160952
    Cytarabine-daunorubicin 1256639-86-7
    Cytarabine-daunorubicin (CPX 351) is a Liposomal formulation prepared from Cytarabine (HY-13605) and Daunorubicin (HY-13062A) at a fixed synergistic molar ratio of 5:1. Cytarabine-daunorubicin improves secondary acute myeloid leukemia. Cytarabine-daunorubicin can be used in research related to secondary acute myeloid leukemia, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia.
    Cytarabine-daunorubicin
  • HY-164534
    SIK2/3-IN-2 1648864-21-4
    SIK2/3-IN-2 (compound 12, compound I-200) is a potent SIK2/3 inhibitor (SIK2 IC50 = 65 nM, SIK3 IC50 = 14 nM). SIK2/3-IN-2 is also a p21-activated protein kinase (PAK) 1 inhibitor with a Ki of 20.7 nM. SIK2/3-IN-2 can be used for hyperproliferative diseases and cancer research, such as Paclitaxel (HY-B0015)-resistant ovarian cancer.
    SIK2/3-IN-2
  • HY-179687
    JAK2-IN-18 3108318-77-7
    JAK2-IN-18 (Compound example1) is a selective JAK2 inhibitor. JAK2-IN-18 can inhibit JAK-STAT signaling and shows an IC50 of <100 nM for pSTAT5 in HEL9217 cells. JAK2-IN-18 can inhibit the proliferation of abnormally proliferating myeloid cells and can be used for the research of myeloproliferative disorders, such as essential thrombocythemia.
    JAK2-IN-18
  • HY-P991517
    BI-836858
    BI-836858 is a fully human anti-CD33 monoclonal antibody. BI-836858 reduces CD33+ cells via antibody-dependent cellular cytotoxicity (ADCC), blocks downstream signaling of S100A9/CD33, decreases the secretion of immunosuppressive cytokines and reactive oxygen species-induced genomic instability, and restores bone marrow hematopoietic function. BI-836858 is applicable to the research of myelodysplastic syndrome (MDS) and AML.
    BI-836858